FI964537A0 - Menetelmiä peroksinitriitin hajoamiskatalyyttien käyttämiseksi, farmaseuttisia koostumuksia sitä varten - Google Patents

Menetelmiä peroksinitriitin hajoamiskatalyyttien käyttämiseksi, farmaseuttisia koostumuksia sitä varten

Info

Publication number
FI964537A0
FI964537A0 FI964537A FI964537A FI964537A0 FI 964537 A0 FI964537 A0 FI 964537A0 FI 964537 A FI964537 A FI 964537A FI 964537 A FI964537 A FI 964537A FI 964537 A0 FI964537 A0 FI 964537A0
Authority
FI
Finland
Prior art keywords
peroxynitrite
pharmaceutical compositions
methods
same
decomposition catalysts
Prior art date
Application number
FI964537A
Other languages
English (en)
Swedish (sv)
Other versions
FI964537A (fi
Inventor
Michael Keith Stern
Daniela Salvemini
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of FI964537A0 publication Critical patent/FI964537A0/fi
Publication of FI964537A publication Critical patent/FI964537A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI964537A 1994-05-13 1996-11-12 Menetelmiä peroksinitriitin hajoamiskatalyyttien käyttämiseksi, farmaseuttisia koostumuksia sitä varten FI964537A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24249894A 1994-05-13 1994-05-13
PCT/US1995/005886 WO1995031197A1 (en) 1994-05-13 1995-05-09 Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor

Publications (2)

Publication Number Publication Date
FI964537A0 true FI964537A0 (fi) 1996-11-12
FI964537A FI964537A (fi) 1997-01-10

Family

ID=22915009

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964537A FI964537A (fi) 1994-05-13 1996-11-12 Menetelmiä peroksinitriitin hajoamiskatalyyttien käyttämiseksi, farmaseuttisia koostumuksia sitä varten

Country Status (13)

Country Link
EP (1) EP0758892A1 (fi)
JP (1) JPH10500671A (fi)
CN (1) CN1222286C (fi)
AU (1) AU709553B2 (fi)
BR (1) BR9507643A (fi)
CA (1) CA2189528A1 (fi)
CZ (1) CZ323496A3 (fi)
FI (1) FI964537A (fi)
HU (1) HUT76327A (fi)
NO (1) NO964793L (fi)
NZ (1) NZ285648A (fi)
PL (1) PL317192A1 (fi)
WO (1) WO1995031197A1 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
AU3758695A (en) * 1994-09-20 1996-04-09 Duke University Oxidoreductase activity of manganic porphyrins
ES2198767T3 (es) 1997-11-03 2004-02-01 Duke University Porfirinas sustituidas.
ATE311206T1 (de) 1998-04-24 2005-12-15 Univ Duke Substituierte porphyrine
WO2000009111A2 (en) * 1998-08-11 2000-02-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibitors of amyloid formation
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
EP1013272A1 (en) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Manipulation of the activity of a nitric oxide radical production pathway for the treatment of diseases associated with the presence of oxygen free radicals
JP4501128B2 (ja) 1999-01-25 2010-07-14 ナショナル ジュウィッシュ ヘルス 置換ポルフィリン
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
FR2806911B1 (fr) * 2000-03-28 2003-01-10 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
CA2436245C (en) * 2001-01-19 2013-04-23 National Jewish Medical And Research Center Medicament for protection in radiotherapy
AU2002312194B8 (en) 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
AU2003237500A1 (en) 2002-06-07 2003-12-22 Duke University Substituted porphyrins
DE10240343A1 (de) * 2002-08-27 2004-03-11 Schering Ag Peroxynitrit-Umlagerungskatalysatoren
US6946466B2 (en) * 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US7705040B2 (en) * 2005-10-07 2010-04-27 The University Of Hong Kong Reagents for highly specific detection of peroxynitrite
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US8232267B2 (en) 2006-10-06 2012-07-31 The Trustees Of Princeton University Porphyrin catalysts and methods of use thereof
WO2009027965A1 (en) * 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
EP2300003B1 (en) 2008-05-23 2014-03-05 National Jewish Health Compounds for use in treating injury associated with exposure to an alkylating species
AU2014374361B9 (en) 2013-12-31 2019-07-04 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
RU2557655C1 (ru) * 2014-06-10 2015-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ФГБОУ ВПО "ИГХТУ") Никелевый комплекс 5,10,15,20-тетракис[3',5'-ди(2"-метилбутилокси)фенил]-порфина, проявляющий свойство стационарной фазы для газовой хроматографии
CN107573259A (zh) * 2017-09-25 2018-01-12 沅江华龙催化科技有限公司 一种金属卟啉催化芳香烯烃合成芳香腈的方法
EP4059496A1 (en) * 2021-03-18 2022-09-21 Institut Pasteur Mntbap and m(iii) n-substituted pyridylporphyrins (mnps) for use in reversing sepsis-induced microglial cells alteration(s), associated long-term cognitive impairment, and/or for treating sepsis or sepsis-associated encephalopathy (sae), and/or related short and/or long-term symptoms or complications thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0210351B1 (en) * 1985-04-30 1993-07-21 Nippon Petrochemicals Co., Ltd. Use of porphyrin derivatives in the detection and treatment of tumours
CA1340951C (en) * 1986-01-02 2000-04-11 Alan R. Moragn Production and use of purpurins, chlorins and purpurin-and chlorin-containing compositions
US4866054A (en) * 1986-05-13 1989-09-12 Chai-Tech Corporation Antioxidant metallo-organic treatment of inflammation
JPH02501740A (ja) * 1987-09-08 1990-06-14 ザ ロックフェラー ユニバーシティ 腫瘍治療における毒性作用を消去するためのメタロポルフィリンの使用
EP0484027B1 (en) * 1990-11-02 1996-12-18 Zeneca Limited Polysubstituted phthalocyanines
JPH06504041A (ja) * 1990-11-14 1994-05-12 ユー・エー・ビー・リサーチ　ファウンデーション 虚血性傷害を減少させる方法と組成
FR2676738B1 (fr) * 1991-05-22 1995-05-05 Ir2M Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
GB9111689D0 (en) * 1991-05-31 1991-07-24 Johnson Matthey Plc Gallium compounds
WO1993002090A1 (en) * 1991-07-19 1993-02-04 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1993010777A1 (en) * 1991-11-25 1993-06-10 Albion International, Inc. Composition and method for reducing free radical cellular oxidative stress in warm-blooded animals
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0758892A1 (en) 1997-02-26
HUT76327A (en) 1997-08-28
JPH10500671A (ja) 1998-01-20
BR9507643A (pt) 1997-09-23
NO964793L (no) 1997-01-06
FI964537A (fi) 1997-01-10
PL317192A1 (en) 1997-03-17
NO964793D0 (no) 1996-11-12
WO1995031197A1 (en) 1995-11-23
AU2512095A (en) 1995-12-05
AU709553B2 (en) 1999-09-02
NZ285648A (en) 1999-08-30
CN1152871A (zh) 1997-06-25
HU9603140D0 (en) 1997-01-28
CZ323496A3 (en) 1997-10-15
CA2189528A1 (en) 1995-11-23
CN1222286C (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
FI964537A0 (fi) Menetelmiä peroksinitriitin hajoamiskatalyyttien käyttämiseksi, farmaseuttisia koostumuksia sitä varten
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
HUP9900625A3 (en) Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds
HUP0003309A3 (en) Imidazolyl-cyclic acetals, process for producing them and pharmaceutical compositions containing the same
HUP9902455A3 (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
DE59507593D1 (de) Gaserzeugendes, azidfreies Stoffgemisch
NO976121L (no) FremgangsmÕte for fremstilling av karbonylforbindelser
NO983068D0 (no) FremgangsmÕte for fremstilling av bis-syklopentadienyl-dien komplekser
NO904222D0 (no) Fremgangsmaate for fremstilling av benzodiazepiner.
FI973644A (fi) Uusi menetelmä 2,3-dihydrobentsofuranolijohdannaisten valmistamiseksi
ZA97872B (en) Use of pyrolidine derivatives for the manufacture of medicaments.
NO941648D0 (no) Fremgangsmåte for fremstilling av katalysatorer
FI956058A (fi) Menetelmä glutaaridialdehydin valmistamiseksi
NO985535D0 (no) FremgangsmÕte for fremstilling av 1,3-alkandioler
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
FI101472B1 (fi) Menetelmä 1,3-diolien monoesterien valmistamiseksi
DZ2302A1 (fr) Produit pharmaceutique cristallin.
FI964829A0 (fi) Menetelmä 2,2,4-trimetyyli-1,3-pentaanidioli-isobutyraatin valmistamiseksi
FI961178A (fi) Menetelmä syklisten cis-1-amino-2-alkanolien valmistamiseksi
TR199601018A1 (tr) Farmasötik bilesikler.
FI972694A0 (fi) Uusi menetelmä sameridiinin valmistamiseksi
FI971964A0 (fi) Menetelmä 1-halo-3-trialkyylisilasnyylibentseenijohdannaisten valmistamiseksi
FI934317A0 (fi) Farmaceutiska sammansaettningar, vilka innehaoller ej-joniska ytaktiva aemnen
FI961717A (fi) Menetelmä oraalisten, kinoloneja sisältävien valmisteiden valmistamiseksi
NO20003077D0 (no) FremgangsmÕte for fremstilling av klorbenzooksazolen

Legal Events

Date Code Title Description
MA Patent expired